Figure S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Year: 2023
Type: other
Abstract: Biomarker changes over time. A, Variations in chemokines IP-10, eotaxin and TNF-β in pg/ml. B, Variation in CD8+T-cells, m-MDSC, PMN-MDSC, regulatory T-cells (Tregs) expressed as percentage of total CD45+ cells, ratio of CD8+/ PMN-MDSC. C, Relative changes in peripheral blood cells (PMN-MDSC, CD8+ T-cell, CD8+ T cells/T-reg) and IL-12p70. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID and dose level 3 is propranolol 30 mg BID. Asterix show significant values at different time points compared to baseline in different dose levels.
Authors: Shipra Gandhi, Manu R. Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen, Cheryl Allen, Joseph D. Tario, Paul K. Wallace, Carlos D. Cedeno, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J. Drabick, Mark J. Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A. Repasky, Marc S. Ernstoff
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362432265